(EQH) Axa Equitable Holdings - NYSE
Sector: Financial Services | Industry: Asset Management | Exchange: NYSE (USA) | Market Cap: 12.649m USD | Total Return: -19.4% in 12m
Avg Turnover: 187M
EPS Trend: 82.3%
Qual. Beats: 0
Rev. Trend: 56.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality
Equitable Holdings, Inc. (EQH) is a diversified financial services company headquartered in New York, operating through six business segments: Individual Retirement, Group Retirement, Asset Management, Protection Solutions, Wealth Management, and Legacy. The company primarily serves affluent and high-net-worth individuals through variable annuity products, while also providing retirement services to plans sponsored by educational entities, municipalities, non-profit organizations, and small-to-medium-sized businesses. Its offerings span investment management, life insurance (including VUL, COLI, IUL, and term life), employee benefits, and advisory/financial planning services, with the Legacy segment housing its capital-intensive fixed-rate GMxB business. The company was founded in 1859, was formerly known as AXA Equitable Holdings, Inc., and adopted its current name in January 2020.
As a large-cap U.S. financials company listed on the NYSE, EQH operates within the diversified financial services sub-industry, generating revenue through a mix of insurance premiums, asset-based fees, and advisory commissions. Variable annuities, a core product for the firm, are hybrid insurance-investment contracts that have faced increased regulatory scrutiny in recent years regarding living and death benefit guarantees.
- Interest rate path drives spread income and hedging costs
- Equity market gains lift Asset Management AUM and fees
- Legacy GMxB runoff releases capital for shareholder returns
| Net Income: -822.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA -0.54 > 1.0 |
| NWC/Revenue: -536.6% < 20% (prev -450.7%; Δ -85.90% < -1%) |
| CFO/TA 0.00 > 3% & CFO 840.0m > Net Income -822.0m |
| Net Debt (-43.4b) to EBITDA (634.0m): -68.53 < 3 |
| Current Ratio: 0.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (283.8m) vs 12m ago -9.01% < -2% |
| Gross Margin: 63.55% > 18% (prev 68.85%; Δ -5.30% > 0.5%) |
| Asset Turnover: 3.79% > 50% (prev 4.87%; Δ -1.09% > 0%) |
| Interest Coverage Ratio: -1.08 > 6 (EBIT TTM -249.0m / Interest Expense TTM 231.0m) |
| A: -0.20 (Total Current Assets 76.2b - Total Current Liabilities 137b) / Total Assets 310b |
| B: 0.03 (Retained Earnings 8.78b / Total Assets 310b) |
| C: -0.00 (EBIT TTM -249.0m / Avg Total Assets 299b) |
| D: 0.00 (Book Value of Equity 273.0m / Total Liabilities 308b) |
| Altman-Z'' = -1.20 = CCC |
| DSRI: 2.80 (Receivables 25.2b/11.1b, Revenue 11.3b/14.0b) |
| GMI: 1.08 (GM 68.85% / 63.55%) |
| AQI: 0.93 (AQ_t 0.75 / AQ_t-1 0.81) |
| SGI: 0.81 (Revenue 11.3b / 14.0b) |
| TATA: -0.01 (NI -822.0m - CFO 840.0m) / TA 310b) |
| Beneish M = -1.65 (Cap -4..+1) = CCC |
As of June 28, 2026, the stock is trading at USD 44.00 with a total of 7,709,736 shares traded. Over the past week, the price has changed by -2.85%, over one month by +4.90%, over three months by +15.03% and over the past year by -19.43%.
Current recommended Stop Loss: 41.70 (which is 5.2% or 1.8 ATR below the current price).
Axa Equitable Holdings has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy EQH.
- StrongBuy: 6
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 58.4 | 32.8% |
P/E Forward = 4.5851
P/S = 1.117
P/B = 164.1395
Revenue TTM = 11.3b USD
EBIT TTM = -249.0m USD
EBITDA TTM = 634.0m USD
Long Term Debt = 6.93b USD (from longTermDebt, last quarter)
Short Term Debt = 25.0m USD (from shortTermDebt, last fiscal year)
Debt = 6.93b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -43.4b USD (calculated: Debt 6.93b - CCE 50.4b)
Enterprise Value = 12.6b USD (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = -1.08 (Ebit TTM -249.0m / Interest Expense TTM 231.0m)
EV/FCF = 15.67x (Enterprise Value 12.6b / FCF TTM 807.0m)
FCF Yield = 6.38% (FCF TTM 807.0m / Enterprise Value 12.6b)
FCF Margin = 7.13% (FCF TTM 807.0m / Revenue TTM 11.3b)
Net Margin = -7.26% (Net Income TTM -822.0m / Revenue TTM 11.3b)
Gross Margin = 63.55% ((Revenue TTM 11.3b - Cost of Revenue TTM 4.13b) / Revenue TTM)
Gross Margin QoQ = 90.69% (prev 88.07%)
Tobins Q-Ratio = 0.04 (Enterprise Value 12.6b / Total Assets 310b)
Interest Expense / Debt = 3.33% (Interest Expense 231.0m / Debt 6.93b)
Taxrate = 17.59% (156.0m / 887.0m)
NOPAT = -205.2m (EBIT -249.0m * (1 - 17.59%)) [loss with tax shield]
Current Ratio = 0.56 (Total Current Assets 76.2b / Total Current Liabilities 137b)
Debt / Equity = 25.37 (Debt 6.93b / totalStockholderEquity, last quarter 273.0m)
Debt / EBITDA = -68.53 (Net Debt -43.4b / EBITDA 634.0m)
Debt / FCF = -53.84 (Net Debt -43.4b / FCF TTM 807.0m)
Total Stockholder Equity = 374.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.28% (Net Income -822.0m / Total Assets 310b)
RoE = -219.8% (Net Income TTM -822.0m / Total Stockholder Equity 374.0m)
RoCE = -3.41% (EBIT -249.0m / Capital Employed (Equity 374.0m + L.T.Debt 6.93b))
RoIC = -0.12% (negative operating profit) (NOPAT -205.2m / Invested Capital 173b)
WACC = 7.70% (E(12.6b)/V(19.6b) * Re(10.41%) + D(6.93b)/V(19.6b) * Rd(3.33%) * (1-Tc(0.18)))
Discount Rate = 10.41% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -98.88 | Cagr: -7.38%
[DCF] Terminal Value 73.10% ; FCFF base≈1.41b ; Y1≈1.23b ; Y5≈996.3m
[DCF] Fair Price = 211.1 (EV 16.0b - Net Debt -43.4b = Equity 59.4b / Shares 281.5m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 82.33 | EPS CAGR: 10.39% | SUE: 0.09 | # QB: 0
Revenue Correlation: 56.68 | Revenue CAGR: 6.80% | SUE: 0.22 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.68 | Chg30d=+0.18% | Revisions=-50% | Analysts=13
EPS next Quarter (2026-09-30): EPS=1.84 | Chg30d=+0.93% | Revisions=-17% | Analysts=12
EPS current Year (2026-12-31): EPS=7.07 | Chg30d=+0.54% | Revisions=-41% | GrowthEPS=+25.4% | GrowthRev=+35.4%
EPS next Year (2027-12-31): EPS=8.80 | Chg30d=+0.66% | Revisions=-29% | GrowthEPS=+24.4% | GrowthRev=+8.4%
[Analyst] Revisions Ratio: -50%